BR9607289A - Composiçoes farmacêuticas para administraçao controlada de receptores solúveis - Google Patents

Composiçoes farmacêuticas para administraçao controlada de receptores solúveis

Info

Publication number: BR9607289A
Authority: BR; Brazil
Prior art keywords: pct; pharmaceutical compositions; soluble receptors; ligand; sec
Prior art date: 1995-03-01

Application number

BR9607289A

Other languages

English (en)

Inventor

David Wallach Rom Eliaz

Josef Kost

Original Assignee

Univ Ben Gurion

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-01

Filing date

1996-03-01

Publication date

1998-06-23

1996-03-01 Application filed by Univ Ben Gurion, Yeda Res & Dev filed Critical Univ Ben Gurion

1998-06-23 Publication of BR9607289A publication Critical patent/BR9607289A/pt

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000003446 ligand Substances 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
230000002939 deleterious effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000006386 neutralization reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BR9607289A 1995-03-01 1996-03-01 Composiçoes farmacêuticas para administraçao controlada de receptores solúveis BR9607289A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL11283495A IL112834A (en)	1995-03-01	1995-03-01	Pharmaceutical compositions for controlled release of soluble receptors
PCT/US1996/003121 WO1996026738A1 (en)	1995-03-01	1996-03-01	Pharmaceutical compositions for controlled release of soluble receptors

Publications (1)

Publication Number	Publication Date
BR9607289A true BR9607289A (pt)	1998-06-23

Family

ID=11067150

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9607289A BR9607289A (pt)	1995-03-01	1996-03-01	Composiçoes farmacêuticas para administraçao controlada de receptores solúveis

Country Status (19)

Country	Link
US (1)	US6083534A (pt)
EP (1)	EP0812208B1 (pt)
JP (1)	JP4447052B2 (pt)
KR (1)	KR100417650B1 (pt)
CN (1)	CN1133464C (pt)
AT (1)	ATE415941T1 (pt)
AU (1)	AU692384B2 (pt)
BR (1)	BR9607289A (pt)
CA (1)	CA2213560C (pt)
DE (1)	DE69637768D1 (pt)
DK (1)	DK0812208T3 (pt)
EA (1)	EA199700206A1 (pt)
ES (1)	ES2318849T3 (pt)
IL (1)	IL112834A (pt)
MX (1)	MX9706626A (pt)
NO (2)	NO323003B1 (pt)
PT (1)	PT812208E (pt)
UA (1)	UA44761C2 (pt)
WO (1)	WO1996026738A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7091181B2 (en)	1994-12-12	2006-08-15	Omeros Corporation	Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
BR9509985A (pt)	1995-12-12	1998-11-03	Omeros Med Sys Inc	Solução para irrigação e método para inibição de dor inflamação e esparmo
US7067144B2 (en) *	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
EP1206275B1 (en) *	1998-11-05	2007-09-05	Omeros Corporation	Irrigation solution and method for inhibition of pain and inflammation
US20040220103A1 (en) *	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
US7807211B2 (en) *	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1216037A2 (en) *	1999-09-21	2002-06-26	Emory University	Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8632845B2 (en) *	2000-12-28	2014-01-21	Abbott Cardiovascular Systems Inc.	Method of drying bioabsorbable coating over stents
PT1471974E (pt) *	2002-02-06	2007-10-12	Ares Trading Sa	Factor de necrose tumural combinado com interferão em doenças desmielinizantes
PT2561860T (pt) *	2002-05-31	2018-05-08	Titan Pharmaceuticals Inc	Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
CA2490007C (en) *	2002-07-19	2011-05-24	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
CA2520613C (en)	2003-03-31	2012-12-04	Titan Pharmaceuticals, Inc.	Implantable polymeric device for sustained release of dopamine agonist
US7892563B2 (en) *	2003-05-20	2011-02-22	Wyeth Holdings Corporation	Methods for treatment of severe acute respiratory syndrome (SARS)
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US20060046960A1 (en) *	2004-09-02	2006-03-02	Mckay William F	Controlled and directed local delivery of anti-inflammatory compositions
US20060046961A1 (en) *	2004-09-02	2006-03-02	Mckay William F	Controlled and directed local delivery of anti-inflammatory compositions
CN1311818C (zh) *	2004-11-22	2007-04-25	山东蓝金生物工程有限公司	一种抗实体肿瘤的药物组合物
EP1827108B1 (en) *	2004-11-29	2015-04-08	Yeda Research And Development Co., Ltd.	Induction of neurogenesis and stem cell therapy in combination with copolymer 1
US8128952B2 (en) *	2005-01-12	2012-03-06	Clemson University Research Foundation	Ligand-mediated controlled drug delivery
EP1896072A4 (en) *	2005-06-24	2013-01-09	Univ Duke	SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
US9012605B2 (en)	2006-01-23	2015-04-21	Amgen Inc.	Crystalline polypeptides
US20090183503A1 (en) *	2008-01-18	2009-07-23	Alberto Verdesi	Exhaust apparatus
BRPI0910850B1 (pt)	2008-04-21	2022-06-14	Otonomy, Inc.	Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
GB2460915B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US8784870B2 (en)	2008-07-21	2014-07-22	Otonomy, Inc.	Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN102105133B (zh)	2008-07-21	2015-06-17	奥德纳米有限公司	控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
EP2688910B1 (en)	2011-03-25	2019-05-29	Amgen Inc.	Anti-sclerostin antibody crystals and formulations thereof
EP2844668A1 (en) *	2012-05-03	2015-03-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
WO2014046631A1 (en)	2012-09-19	2014-03-27	Tezcaner Aysen	CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α
WO2015119653A1 (en)	2014-02-04	2015-08-13	Abbott Cardiovascular Systems Inc.	Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
EP3169710A1 (en)	2014-07-14	2017-05-24	Amgen Inc.	Crystalline antibody formulations
WO2016010924A1 (en)	2014-07-14	2016-01-21	Amgen Inc.	Crystalline antibody formulations
US9775978B2 (en)	2014-07-25	2017-10-03	Warsaw Orthopedic, Inc.	Drug delivery device and methods having a retaining member
US9764122B2 (en)	2014-07-25	2017-09-19	Warsaw Orthopedic, Inc.	Drug delivery device and methods having an occluding member
WO2017019907A1 (en)	2015-07-28	2017-02-02	Otonomy, Inc.	Trkb or trkc agonist compositions and methods for the treatment of otic conditions
JP5938762B1 (ja)	2015-09-01	2016-06-22	日揮株式会社	マイクロカプセル製剤及びその製造方法
US10076650B2 (en)	2015-11-23	2018-09-18	Warsaw Orthopedic, Inc.	Enhanced stylet for drug depot injector
USD802755S1 (en)	2016-06-23	2017-11-14	Warsaw Orthopedic, Inc.	Drug pellet cartridge
KR20190024983A (ko)	2016-06-29	2019-03-08	오토노미, 인코포레이티드	트리글리세라이드 귀 제제 및 이의 용도
US10434261B2 (en)	2016-11-08	2019-10-08	Warsaw Orthopedic, Inc.	Drug pellet delivery system and method
CA3087574A1 (en)	2018-01-09	2019-07-18	Otonomy, Inc.	Growth factor otic formulations
WO2019222856A1 (en)	2018-05-24	2019-11-28	Nureva Inc.	Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en)	2018-05-24	2019-11-28	Celanese EVA Performance Polymers Corporation	Implantable device for sustained release of a macromolecular drug compound
AU2019275406B2 (en)	2018-05-24	2024-11-14	Celanese Eva Performance Polymers Llc	Implantable device for sustained release of a macromolecular drug compound
WO2022231930A1 (en)	2021-04-26	2022-11-03	Celanese Eva Performance Polymers Llc	Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5114719A (en) *	1987-04-29	1992-05-19	Sabel Bernhard A	Extended drug delivery of small, water-soluble molecules
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
IL98078A0 (en) *	1991-05-07	1992-06-21	Yeda Res & Dev	Pharmaceutical compositions comprising an anticytokyne
SE8804164A0 (sv) *	1988-11-17	1990-05-18	Per Prisell	Farmaceutisk beredning
US5324519A (en) *	1989-07-24	1994-06-28	Atrix Laboratories, Inc.	Biodegradable polymer composition
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5478564A (en) *	1990-02-22	1995-12-26	Teva Pharmaceutical Industries, Ltd.	Preparation of microparticles for controlled release of water-soluble substances
US5206023A (en) *	1991-01-31	1993-04-27	Robert F. Shaw	Method and compositions for the treatment and repair of defects or lesions in cartilage
US5330768A (en) *	1991-07-05	1994-07-19	Massachusetts Institute Of Technology	Controlled drug delivery using polymer/pluronic blends
IL99120A0 (en) *	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5470582A (en) *	1992-02-07	1995-11-28	Syntex (U.S.A.) Inc.	Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP0620739A4 (en) *	1992-09-15	1997-01-15	Immunex Corp	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
EP0646000A4 (en) *	1992-11-16	1997-05-02	Univ Mercer	COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.

1995
- 1995-03-01 IL IL11283495A patent/IL112834A/xx not_active IP Right Cessation
1996
- 1996-01-03 UA UA97094438A patent/UA44761C2/uk unknown
- 1996-03-01 MX MX9706626A patent/MX9706626A/es unknown
- 1996-03-01 AU AU53039/96A patent/AU692384B2/en not_active Expired
- 1996-03-01 DK DK96909604T patent/DK0812208T3/da active
- 1996-03-01 CN CNB961934379A patent/CN1133464C/zh not_active Expired - Lifetime
- 1996-03-01 KR KR1019970706046A patent/KR100417650B1/ko not_active Expired - Lifetime
- 1996-03-01 AT AT96909604T patent/ATE415941T1/de active
- 1996-03-01 JP JP52645796A patent/JP4447052B2/ja not_active Expired - Lifetime
- 1996-03-01 DE DE69637768T patent/DE69637768D1/de not_active Expired - Lifetime
- 1996-03-01 EP EP96909604A patent/EP0812208B1/en not_active Expired - Lifetime
- 1996-03-01 PT PT96909604T patent/PT812208E/pt unknown
- 1996-03-01 CA CA2213560A patent/CA2213560C/en not_active Expired - Lifetime
- 1996-03-01 ES ES96909604T patent/ES2318849T3/es not_active Expired - Lifetime
- 1996-03-01 US US08/894,913 patent/US6083534A/en not_active Expired - Lifetime
- 1996-03-01 EA EA199700206A patent/EA199700206A1/ru unknown
- 1996-03-01 BR BR9607289A patent/BR9607289A/pt not_active IP Right Cessation
- 1996-03-01 WO PCT/US1996/003121 patent/WO1996026738A1/en not_active Ceased
1997
- 1997-08-19 NO NO19973812A patent/NO323003B1/no not_active IP Right Cessation
2005
- 2005-12-27 NO NO20056197A patent/NO328034B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL112834A0 (en)	1995-06-29
MX9706626A (es)	1998-02-28
CN1182369A (zh)	1998-05-20
DE69637768D1 (de)	2009-01-15
PT812208E (pt)	2009-02-06
NO323003B1 (no)	2006-12-18
JPH11501306A (ja)	1999-02-02
JP4447052B2 (ja)	2010-04-07
NO973812L (no)	1997-11-03
ES2318849T3 (es)	2009-05-01
EP0812208B1 (en)	2008-12-03
ATE415941T1 (de)	2008-12-15
IL112834A (en)	2000-12-06
NO328034B1 (no)	2009-11-16
NO973812D0 (no)	1997-08-19
AU5303996A (en)	1996-09-18
US6083534A (en)	2000-07-04
CA2213560A1 (en)	1996-09-06
EA199700206A1 (ru)	1998-02-26
CA2213560C (en)	2010-08-24
AU692384B2 (en)	1998-06-04
EP0812208A1 (en)	1997-12-17
KR19980702640A (ko)	1998-08-05
EP0812208A4 (en)	2004-06-30
CN1133464C (zh)	2004-01-07
KR100417650B1 (ko)	2004-05-20
NO20056197L (no)	1997-11-03
DK0812208T3 (da)	2009-03-16
UA44761C2 (uk)	2002-03-15
WO1996026738A1 (en)	1996-09-06

Legal Events

Date	Code	Title	Description
2003-06-10	EG	Technical examination (opinion): publication of technical examination (opinion)
2003-10-21	FB36	Technical and formal requirements: requirement - article 36 of industrial property law
2004-02-25	HJEG	Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
2004-11-16	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2005-04-26	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
2016-05-03	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 01/03/2016

Publication	Publication Date	Title
DE69637768D1 (de)	2009-01-15	Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
GB2246295B (en)	1994-05-11	Continuous release pharmaceutical compositions
UA29563C2 (uk)	2000-11-15	Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
FR2727015B1 (fr)	1997-08-22	Compositions pharmaceutiques liquides a base d'ondansetron
GR3036798T3 (en)	2002-01-31	Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
PT772441E (pt)	2002-08-30	Antagonistas da progesterona e gestagene para o tratamento da endometriose e leiomyomata uteri
DE69506007D1 (de)	1998-12-17	Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
ATE198152T1 (de)	2001-01-15	Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
DE69227259D1 (de)	1998-11-12	Film zur lokalen arzneistoffabgabe für periodontale behandlung
SI0999843T1 (en)	2005-02-28	Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
DE69228997D1 (de)	1999-05-27	Menschliche il-3-varianten
DE69634080D1 (de)	2005-01-27	Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20032906B (en)	2003-02-25	Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure
Fischer et al.	1986	Cement burns: rare or rarely reported?